Canaan Partners
Edit

Canaan Partners

https://www.canaan.com
Last activity: 20.09.2026
Active
Invests in categories: AIDataFinTechITOnlinePlatformSaaSServiceSoftwareTechnology
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With a diversified fund and over 200 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 33+ years. Canaan’s focus areas include Consumer Tech, Enterprise, Fintech, Frontier Tech and Life Sciences. To learn more about our people and our portfolio, please visit canaan.com.
News
808
Portfolio
278
Mentions
406
Location: United States, California, San Francisco
Employees: 11-50
Founded date: 1987
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A; Series B; Series C; Series D; Series E; Grant

Portfolio 278

DateNameWebsiteTotal RaisedLocation
14.09.2026Solstice O...solsticeoncology.com--
11.08.2026MC Science...mcsciences.com--
07.08.2026Mate Secur...mate.security$35M-
10.07.2026OpenArtopenart.ai-United Sta...
10.07.2026Safire Tec...safire.co$8MUnited Sta...
10.07.2026Aer Therap...aertherapeutics.com$51.88MUnited Sta...
10.07.2026Reflexworkreflex.com-United Sta...
10.07.2026WiseLayerwiselayer.com$7.2M-
10.07.2026DoorStepdoorstep.ai--
10.07.2026Arcadearcade.ai$102MUnited Sta...
Show more

News 808

DateTitleDescription
20.09.2026Begun, the AI Assistant War Has-
10.09.2026Transforming Early-Stage Colon Cancer Outcomes: Why We Invested in Solstice Oncology-
22.08.2026Engineering Intelligence for the Physical World-
22.08.2026Creating Without Limits-
22.08.2026Building Fast Planes, Fast-
22.08.2026Creating a New Category for Luxury Resale-
22.08.2026Redefining Hope from Day One-
22.08.2026Johnson & Johnson Acquires Halda for $3.05B-
22.08.2026Redefining General Robot Intelligence-
22.08.2026Accelerating the Path to Fault-Tolerant Quantum Computing-
Show more

Mentions in press and media 406

DateTitleDescription
09.09.2026Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology TherapyPorustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer Phase 2 trial of porustobart for colon cancer ...
09.09.2026Venture Capital & Startup Funding Roundup, September 9, 2026: Coatue, Andreessen Horowitz, Greylock, Kleiner Perkins, Sequoia & MoreVenture capital’s center of gravity today isn’t in one neat category called AI. It is moving toward companies that control high-value workflows: legal work, sales, wealth management, cybersecurity, industrial production and even weather-ris...
04.08.2026Actualyze AI Raises $7M in Seed FundingActualyze AI, a Pasadena, CA-based provider of an enterprise AI platform, raised $7M in Seed funding. Backers included Storm Ventures, Canaan Partners, Morado Ventures, and Jerry Yang’s AME Cloud Ventures. The company intends to use the fun...
03.08.2026Mate Security Raises $35M in Series A FundingMate Security, a Tel Aviv, Israel-based developer of an AI-driven security operations and autonomous incident response platform, raised $35m in Series A funding. The round, which brought total cumulative capital raised to over $50m, was led...
24.07.2026Terra Quantum and Apex.AI Demonstrate Quantum-Safe Security for Long-Lived, Cloud-Connected, Software-Defined SystemsSuccessful implementation demonstrates secure edge-to-cloud communication using NIST-standardized post-quantum cryptography while preserving existing application architectures and software investments. ST. GALLEN, Switzerland and PALO ALTO,...
14.07.2026Draig Therapeutics Closes $65 Million Series B To Advance AMPA And GABAA Receptor Modulators In Neuropsychiatric DisordersDraig Therapeutics, a clinical-stage biopharmaceutical company co-founded by Cardiff University and SV Health Investors and headquartered across Newton, Massachusetts and Cardiff, United Kingdom, has closed an oversubscribed $65 million Ser...
14.07.2026Draig Therapeutics Raises $65 Million Series B To Advance Neuropsychiatric TherapiesDraig Therapeutics announced the closing of an oversubscribed $65 million Series B financing to accelerate development of its pipeline of neuropsychiatric therapies. The round was led by new investor Deep Track Capital, with participation f...
22.06.2026Vedana Therapeutics Raises $46M in Series A FundingVedana Therapeutics, a Seattle, WA-based biotechnology company developing new therapies for migraine prevention, raised $46M in Series A funding. The round was led by Westlake BioPartners and Canaan Partners, with participation from Dawn Bi...
19.06.2026HeyMilo AI Secures $6M for Advanced Recruiting AutomationHeyMilo AI secured $6 million. This funding fuels expansion of its agentic recruiting platform. New AI agents are now available. These agents automate candidate screening for high-volume roles. The platform tackles the challenge of AI-drive...
19.06.2026Vedana Therapeutics Raises $46 Million To Advance Next-Generation Migraine TherapiesVedana Therapeutics emerged from stealth with $46 million in Series A funding to advance next-generation therapies for migraine prevention. The funding round was co-led by Westlake BioPartners and Canaan Partners, with participation from Da...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In